Related Experiment Videos
Peripheral thyroid hormones and response to selective serotonin reuptake inhibitors
Michael Gitlin1, Lori L Altshuler, Mark A Frye
1Department of Psychiatry, UCLA School of Medicine, Los Angeles, CA 90095, USA. mgitlin@mednet.ucla.edu
Journal of Psychiatry & Neuroscience : JPN
|October 16, 2004
Summary
Baseline thyroid-stimulating hormone (TSH) levels predict antidepressant response in major depression. Lower TSH indicates a better response to selective serotonin reuptake inhibitors (SSRIs), suggesting optimal thyroid function is key for treatment efficacy.
Area of Science:
- Neuroendocrinology
- Psychopharmacology
Background:
- Selective serotonin reuptake inhibitors (SSRIs) are common treatments for major depression.
- Thyroid function plays a role in mood regulation and can be affected by psychiatric conditions.
Purpose of the Study:
- To investigate the relationship between baseline thyroid function and patient response to SSRI antidepressants.
- To assess the impact of SSRIs on thyroid hormone levels.
Main Methods:
- 19 subjects with major depression received open-label sertraline or fluoxetine.
- Thyroid-stimulating hormone (TSH), triiodothyronine (T3), thyroxine (T4), and free T4 levels were measured pre- and post-treatment.
- Depression severity was assessed using Hamilton Depression Rating Scale (Ham-D) and Clinical Global Impressions (CGI) scores.
Main Results:
- Baseline TSH levels showed a strong correlation with treatment response (r = 0.64, p = 0.003).
- Lower baseline TSH values were associated with greater improvement in depressive symptoms.
- While thyroid hormone levels decreased during SSRI treatment, these changes did not correlate with clinical improvement.
Conclusions:
- Serum TSH at baseline may serve as a predictor of SSRI antidepressant treatment response.
- Optimal thyroid function, potentially beyond standard laboratory ranges, may be crucial for achieving the best outcomes with SSRIs.